ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1882

Thymus and Activation-Regulated Chemokine (TARC) As Biomarker for IgG4-Related Disease

Masataka Umeda1,2, Tomoki Origuchi3, Shinya Kawashiri1,4, Tomohiro Koga1,5, Kunihiro Ichinose1, Yushiro Endo1, Sousuke Tsuji1, Ayuko Takatani1, Takashi Igawa1, Toshimasa Shimizu1, Shoichi Fukui1,4, Remi Sumiyoshi1, Ayako Nishino1,6, Naoki Iwamoto1, Mami Tamai1, Hideki Nakamura1 and Atsushi Kawakami1, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Medical Education Development Center, Nagasaki University Hospital, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, 4Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, 6Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: biomarkers and chemokines, IgG4 Related Disease, Plasmablasts

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: TARC, also known as chemokine ligand 17 (CCR17), is expressed in the thymus and is produced by dendritic cells, endothelial cells, keratinocytes and fibroblasts. TARC has affinity as a ligand for CCR4 and CCR8, which are predominantly expressed by Th2 cells. High serum concentration of TARC is determined in allergic diseases such as atopic dermatitis and bronchial asthma. Several studies have reported frequent atopic symptoms among patients with IgG4-related disease (IgG4-RD). We investigated the role of TARC as a biomarker in IgG4-RD, in which Th2 cytokines associate in disease states.

Methods: We evaluated the serum concentration of TARC from 26 IgG4-RD patients, 22 healthy controls (HC) by ELISA. We also analyzed the correlations between TARC concentration and clinical parameters. To investigate the biological effect of TARC toward pathogenesis in IgG4-RD, in vitro induction of plasmablasts from peripheral blood mononuclear cells (PBMCs) in patients with IgG4-RD by TARC was evaluated.

Results: We found that the serum concentration of TARC in the IgG4-RD was significantly higher than HC (IgG4-RD mean 493.9 ng/mlCHC mean 262.0 ng/mlCp<0.001). ROC curve for TARC distinguish IgG4-RD from HC, the cutoff value 296.5 ng/ml (sensitivity 80.8%, specificity 72.7%). Serum concentration of TARC from IgG4-RD positively correlated with number of organ involvement (Fig. 1) whereas showed the correlation neither with serum IgG4 nor eosinophil number in peripheral blood. In addition, no difference in TARC concentration was found among IgG4-RD patients with or without atopic symptoms. TARC in vitro clearly induced the formation of plasmablasts from patients with IgG4-RD (Fig. 2).

Conclusion: Collectively, our data suggest that TARC is an essential Th2 cytokine in patients with IgD4-RD. TARC may be involved in the development of IgG4-RD through an aberrant induction of plasmablasts.

Fig1.jpg Fig2.jpg


Disclosure: M. Umeda, None; T. Origuchi, None; S. Kawashiri, None; T. Koga, None; K. Ichinose, None; Y. Endo, None; S. Tsuji, None; A. Takatani, None; T. Igawa, None; T. Shimizu, None; S. Fukui, None; R. Sumiyoshi, None; A. Nishino, None; N. Iwamoto, None; M. Tamai, None; H. Nakamura, None; A. Kawakami, None.

To cite this abstract in AMA style:

Umeda M, Origuchi T, Kawashiri S, Koga T, Ichinose K, Endo Y, Tsuji S, Takatani A, Igawa T, Shimizu T, Fukui S, Sumiyoshi R, Nishino A, Iwamoto N, Tamai M, Nakamura H, Kawakami A. Thymus and Activation-Regulated Chemokine (TARC) As Biomarker for IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/thymus-and-activation-regulated-chemokine-tarc-as-biomarker-for-igg4-related-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thymus-and-activation-regulated-chemokine-tarc-as-biomarker-for-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology